Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.38 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (megakaryocytes) | 0.10 |
| chemistry Open Targets | compounds already reach it: bay-1161909, bay-1217389 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 707 | 0.91 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 0714
Sealed predictions
- TTK in dopamine neurons, braak+0.26 (p 0.502) → +0.63 (p 0.068)receipt 0722
Swarm cases
receipt 0722: TTK in dopamine neurons, braak
- power
- full sample +0.43 (p 0.077, n 18), 95% CI -0.05 to +0.75. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.39 (p 0.107, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.39 (p 0.105, n 18). could be the mix.
- skeptic
- leave-one-out range +0.35 to +0.59, sign flips 0; without severely affected donors +0.43 (p 0.077, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for TTK in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts